Alumis (ALMS) Retained Earnings (2023 - 2026)
Alumis (ALMS) posted quarterly Retained Earnings of -$901.9 million for Q4 2025, down 36.95% year-over-year from -$1.4 billion in Q4 2024, and down 11.49% quarter-over-quarter from -$808.9 million in Q3 2025.
Alumis (ALMS) Retained Earnings (2023 - 2026) Analysis & Trends
Alumis (ALMS) has reported Retained Earnings for 3 consecutive years, with -$901.9 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Retained Earnings fell 36.95% year-over-year to -$901.9 million; the TTM figure through Dec 2025 stood at -$901.9 million (down 36.95% YoY), while the FY2025 annual figure was -$901.9 million, down 36.95% from the prior year.
- Retained Earnings declined to -$901.9 million in Q4 2025 per ALMS's latest filing, from -$808.9 million in the prior quarter.
- Across five years, Retained Earnings topped out at $925.8 million in Q1 2025 and bottomed at -$901.9 million in Q4 2025.
- Historically, Retained Earnings has averaged -$326.5 million across 3 years, with a median of -$564.6 million in 2024.
- Annual changes were most pronounced in 2024 — Retained Earnings plunged 32927650.0% — and 2025, when it tumbled 36.95%.
- Alumis' Retained Earnings stood at $2000.0 in 2023, then slumped by 32927650.0% to -$658.6 million in 2024, then slumped by 36.95% to -$901.9 million in 2025.
- Business Quant data shows ALMS's Retained Earnings at -$901.9 million in Q4 2025, -$808.9 million in Q3 2025, and -$698.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Alumis | 3.25 Bn | 2.75 Bn | - | 1.59 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.59 Bn |
| Dec 31, 2025 | -901.90 Mn |
| Sep 30, 2025 | -808.95 Mn |
| Jun 30, 2025 | -698.20 Mn |
| Mar 31, 2025 | 925.83 Mn |
| Dec 31, 2024 | -658.55 Mn |
| Sep 30, 2024 | 139,000.00 |
| Jun 30, 2024 | -470.68 Mn |
| Dec 31, 2023 | 2,000.00 |